top of page

Q4 2025 Recap + Q1 2026 Preview (Part 1/2)


Greetings Rejuve community,


As we head into the new year, I wanted to take the time to properly reflect on what we accomplished in Q4, because it was one of the most consequential quarters Rejuve has had to date.


A lot moved forward in a very short period of time: governance went live, our token economics became community-directed, our research and AI stack sharpened, and the Rejuve Longevity App took major steps toward real-world, everyday usage. Rather than attempt to cover all of Q4 and the upcoming milestones in a single post, I am splitting it into two parts.

This first post focuses on what happened in Q4 2025 and how it positioned us for 2026.

Part 2 will dive into the Q1 2026 roadmap and what we are actively executing right now.


The central theme across everything you’ll read below is this: Rejuve is now set up for real-world usage of both the RJV token and the Rejuve Longevity App in 2026, with a clear focus on becoming the most useful and credible biohacking tool available.



Governance went live, and the Tokenomics Litepaper set the foundation


We kicked off Q4 with a major milestone: the publishing of our new Tokenomics Litepaper, which is one of the most important infrastructure releases we have made to date. It details, in practical terms, how the RJV token is designed to circulate through the ecosystem, how value is created and recycled, and how governance, incentives, and research participation are meant to reinforce one another as we scale into 2026.


This is also where we first introduced a key new element of our long-term strategy: the Longevity Futures Prediction Market, designed to support real-world RJV usage while incentivizing better forecasting and coordination around longevity outcomes. Importantly, this Litepaper commenced and culminated in the launch and completion of our first ever governance event.


This effort was led by our Ambassador Lead Cole Bartlett, together with a small group of our first Governance ambassadors, and supported by a growing cross-chain community of RJV holders.


We also introduced two concrete governance proposals, and the response from the community was strong and decisive. The voting took place from December 8th to 18th on Snapshot for EVM chains and Clarity for Cardano.



With both votes finalized, we are now firmly in execution mode. Implementation planning is underway, and we will continue to share timelines and milestones as these decisions are rolled out in practice.



Extending token utility into markets for scientific truth

In parallel with governance, Q4 also expanded how we think about token utility and coordination in longevity science more broadly.


We partnered with Episteme, a project building epistemic markets for scientific hypotheses, and submitted a Rejuve-led hypothesis on demonstrating true reversal of aging.


This hypothesis asks whether AI can reliably distinguish true rejuvenation, defined as restoration of lost structure and function due to aging, from improvements in biomarkers or healthspan proxies that may not reflect actual repair. A testnet version is now available.



It is important to clarify that this collaboration is complementary, not competitive, with Rejuve’s own Longevity Futures Prediction Market. Episteme focuses on hypothesis-level epistemic markets across all of science, whereas Rejuve’s prediction market is narrower in domain but broader in scope: it is dedicated specifically to longevity and allows forecasting across interventions, trials, biomarkers, technologies, and ecosystem events, not only formal hypotheses.


Together, these efforts reinforce our refined R&D direction: longevity needs better coordination tools for truth-seeking, not just more metrics or optimistic claims.



Taking Rejuve into the real world: the Longevity Biomarkers Competition


Q4 also marked a major shift in how Rejuve shows up beyond purely digital environments.

At the 2025 Biomarkers of Aging Consortium conference at Harvard, our data scientist and lead researcher Dr. Macsue Jacques announced the Longevity Biomarkers Competition, which will take place during Infinita City’s Infinite Games event in Prospera, Honduras.


Macsue is a researcher both at Rejuve and at Monash University in Australia, reflecting the intentional bridge we are building between decentralized longevity research and academic science.


The competition will be hosted within Infinita City’s Infinite Games, a real-world experimentation environment located in the special economic zone of Prospera.


Prospera has emerged as a focal point for biotech and longevity innovation, home to companies such as Minicircle, Unlimited Bio, and GARM Clinic, and increasingly recognized as a place where leading longevity researchers, founders, and high-profile figures including Bryan Johnson and members of the Kardashian family converge.


This competition represents a core part of our long-term strategy: testing biomarker frameworks, AI models, and intervention signals in real people, over real time, in open and participatory settings. I’ll go deeper into this in Part 2.



Conversations, AMAs, and public education


Q4 was also active on the community and communications front.


I joined the Decoding Longevity podcast with Macsue and Dr. Raghav Sehgal (Yale University) on Decoding Longevity, alongside several AMAs and live sessions, including one with SingularityNET’s Ambassador Program.


These conversations are an important part of how we build Rejuve: through open dialogue, critical discussion, and community participation.



Accelerating AI R&D with a clearer focus


On the R&D side, Q4 marked both acceleration and refinement.



•RejuveAge-Q, a questionnaire-based biological age estimator designed to be accessible without blood tests or wearables


• LinAge2, a blood-based biological age model developed by the National University of Singapore (Jan Gruber and Brian Kennedy’s lab), slated for release in Rejuve Longevity Pro, our premium subscription version of the app


Our model releases reflect a clearer strategy: lowering the barrier to entry for meaningful self-tracking, while also preparing deeper tools for users who want more clinically grounded insight.


We also updated our Technology page to reflect this refined focus on health optimization alongside rejuvenation biomarker development and discovery.




Momentum in the Rejuve Longevity App and preparing for Pro


Q4 brought substantial progress on the Rejuve Longevity App itself, and this is where our ambition to become the #1 biohacking app really starts to show.


We expanded language support to Portuguese, Russian, Spanish, Turkish, and Arabic, with more to come. We shipped meaningful UX and performance improvements, including enhanced profile settings, improvements to the Body Metrics experience to reduce survey burden, and a more intuitive Insights section with clearer trend visualization.


We also announced a partnership with Longevity.Technology’s supplement brand Fueling Longevity Today (FLT), adding more trusted, science-backed options for Rejuve app users.


As part of our broader effort to capture the full picture of human aging, we also added psychosocial isolation as a tracked hallmark of aging within the app, reflecting growing evidence that social and psychological factors are inseparable from long-term healthspan outcomes.


All of this work feeds directly into Rejuve Longevity Pro, our premium subscription tier. We have also added a Pro waitlist directly inside the app, allowing users to signal interest and helping us shape the rollout based on real demand.




Exploring the social and psychological dimensions of longevity: JoyScore


Building on this broader perspective, Q4 also included one of our most interesting real-world pilots to date.


In collaboration with longevity researcher Tina Woods, Rejuve launched the JoyScore Experiment at Frontier Tower, a future-oriented technology hub focused on improving the human condition.


This pilot explored joy, synchrony, and connection as measurable components of health and featured a temporary JoyScore module inside the Rejuve Longevity App, covered in several media publications.



It served as a concrete example of how experiential, exposome-related data can be integrated into our platform and how modular, real-world studies can run directly through the app.



Looking ahead


Q1 is already off to a strong start, with a new app update that includes supplement tracking and the release of RejuveAge-Q now live on both Android and iOS.




Part 2 of this update will cover our Q1 2026 roadmap in detail, including governance execution, Rejuve Longevity Pro rollout, and how the Longevity Biomarkers Competition fits into our broader scientific strategy. Stay tuned!


Thank you for being part of this journey. We are incredibly proud of what was built in Q4, and even more excited about what it unlocks in 2026.




Best wishes and Happy New Year,


Jasmine

 
 
bottom of page